280 results about "Small interfering RNA" patented technology

The invention discloses application of a Wnt2 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. Wnt2 is taken as a research object, the Wnt2 overexpression vector or Wnt2 siRNA is transfected to the ovarian granulosa cells respectively by constructing the Wnt2 overexpression vector and synthesizing small interfering RNA (Wnt2 siRNA), then changes of signal channel gene mRNA and protein level related to ovarian granulosa cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granulosa cells are detected. Results show that Wnt2 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. By exploring the application of the Wnt2 in the ovarian granular cells, the application has good application in researching an ovarian follicle atresia mechanism, initial estrus initiation and the like.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to ITGB1-siRNA lipid nanoparticles and application of the ITGB1-siRNA lipid nanoparticles in anti-angiogenesis treatment. Specifically, the ITGB1-siRNA lipid nanoparticles are successfully prepared, the lipid nanoparticles are loaded with integrin beta1 small interfering RNA (ITGB1-siRNA), are modified with triptolide (TP) and are coupled with anti-Flt1 peptide, so that the lipid nanoparticles can target vascular endothelial cells (VEC) and pericytes of CNV, and a good treatment effect on the CNV is achieved. Therefore, the lipid nanoparticles researched and developed by the invention are expected to become a new choice for treating the CNV-related eye diseases, and have good practical application value.

A siRNA that inhibits the expression of apolipoprotein C3 is provided. Provided are a small interfering RNA (siRNA) for inhibiting expression of APOC3 in a cell, a vector and a cell comprising a nucleotide encoding the same, and a method for treating a disease or symptom associated with expression of APOC3 in a subject using the siRNA, the vector or the cell.

The present disclosure provides systems and methods for separating and characterizing oligonucleotides. Fixed dose combinations of small interfering RNAs can be subjected to denaturing ion pairing reverse phase liquid chromatography using optimal conditions to separate single RNA strands for purity analysis.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The invention discloses application of an SFRP1 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. According to the invention, SFRP1 is taken as a research object, an SFRP1 overexpression vector or siRNA-SFRP1 is respectively transfected to ovarian granular cells by constructing the SFRP1 overexpression vector and synthesizing small interfering RNA (siRNA-SFRP1), then changes of signal channel gene mRNA and protein level related to ovarian granular cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granular cells are detected. Results show that the SFRP1 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. The application of the SFRP1 in the ovarian granular cells is explored, and the SFRP1 has good application in research of an ovarian follicle atresia mechanism, initial estrus initiation and the like.

Embodiments of the present disclosure include compositions and methods for conducting in situ hybridization reactions. In particular, the disclosure provides RNA blocking molecules that enhance the detection of target RNA molecules (e.g., mRNA molecules, micro RNA (miRNA) molecules, small non-coding RNA (sncRNA) molecules, PIWI interacting RNA (piRNA) molecules, and / or small interfering RNA (siRNA) molecules) by reducing the binding of a target probe to non-target RNA molecules in a sample.

The invention discloses a nano hydrogel preparation for packaging small interfering RNA (Ribonucleic Acid) and a preparation method, and belongs to the technical field of nano pesticides. Gold nanoparticles and dendritic mesoporous silica nanoparticles are used as composite carriers to load small interfering RNA, then a pectin solution is used for packaging, and the nano hydrogel preparation is prepared, so that the adhesion of a medicament is greatly enhanced, and rapid permeation and targeted delivery of the medicament are realized.

The disclosure relates to small interfering RNA (siRNA) molecules targeting MAPT and adeno-associated viral (AAV) particles encoding the same for treating tauopathies.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human LPA mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating Lp(a) gene expression.

The invention belongs to the technical field of biological medicines, and particularly relates to application of small interfering RNA (Ribonucleic Acid) of a targeted Zyx gene. The invention provides siRNA (small interfering Ribonucleic Acid) of a targeted Zyx gene, and further provides application of the siRNA in prevention and treatment of fibrosis interstitial lung diseases. Experimental data prove that in a mouse bleomycin model, siRNA of a targeted Zyx gene can effectively improve the survival rate of a sick mouse, alveolar wall thickening, lung substantive thickening and inflammatory cell infiltration of a Zyx knock-down group are not obvious, and pathological damage caused by bleomycin is effectively relieved through knock-down of the Zyx gene; collagen fiber deposition of a Zyx knock-down group is reduced, and the transcription level of fibrosis-related genes is obviously reduced.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.

Provided herein include methods, systems, and compositions for designing a sensor nucleic acid strand of a conditionally activatable small interfering RNA (siRNA) complex as well as the siRNA complexes generated using the method herein described and the component strands. The siRNA complex can be conditionally activated upon a complementary binding to an input nucleic acid strand (e.g. a mRNA of a biomarker gene specific to a target cell) through a sequence in a sensor nucleic acid strand of the nucleic acid complex. The activated nucleic acid complex can release a potent RNAi duplex formed by a core nucleic acid strand and a passenger nucleic acid strand, which can specifically inhibit a target RNA.

The invention discloses application of a kynurenase protein inhibitor in preparation of a medicine for treating radioactive intestinal injury, and belongs to the technical field of biological medicine. The invention discloses the interaction between the kynurenase protein KYNU and the radioactive intestinal injury for the first time, and through gene knockout and expression research of an MAPK signal channel, it is clear that the radioactive intestinal injury can be effectively relieved by inhibiting the expression of the KYNU. Based on the research results, the invention emphatically puts forward that carbidopa can be used as a kynureninase protein KYNU inhibitor and plays a key role in radioactive intestinal injury, so that a new medicine application for treating radioactive intestinal injury is provided aiming at KYNU inhibition; the invention also provides a small interfering RNA (siRNA) for inhibiting the expression of kynureninase protein KYNU for the first time, the KYNU is knocked down, so that the cell proliferation after irradiation can be increased, the cell apoptosis and oxidative stress can be reduced, and KYNU knock-down has a protective effect on radioactive intestinal injury.

Provided are a small interfering RNA (siRNA) for inhibiting expression of proprotein convertase subtilisin / kexin type 9 (PCSK9) in a cell, a vector and a cell comprising a nucleotide encoding the same, and a method for treating a disease or symptom associated with PCSK9 expression in a subject using the siRNA, the vector or the cell.

The invention relates to the field of biological medicine, in particular to an Mmrn1 targeted inhibitor, an inhibition method and application. According to the application disclosed by the invention, firstly, the relationship between the expression of the MMRN1 gene in the acute myelogenous leukemia (AML) and the regulation and control of a'siglecan-siglecc 'axis is creatively disclosed. Therefore, the invention firstly provides a small interfering RNA (Ribonucleic Acid) targeting the Mmrn1 in the leukemia stem cell, and an application of the small interfering RNA in preparation of a'sialic acid glycan-siglecc 'axis immune checkpoint inhibitor.

The present disclosure relates to the field of genetic engineering technology, and more specifically, to a targeting ligand. The targeting ligand provided herein forms a siRNA conjugate with a specific small interfering RNA sequence, which targets ANGPTL3 and degrades ANGPTL3 gene transcripts in cells, thereby reducing ANGPTL3 protein expression. Therefore, the siRNA conjugate formed with the targeting ligand provided herein can be used to prevent and / or treat dyslipidemia.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human FXI mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating FXI gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of FXI or a disease or disorder where FXI plays a role.

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.

The invention discloses siRNA capable of knocking down Pr18a9 gene expression and application of the siRNA, and relates to the technical field of biological medicine. The invention provides a positive-sense strand sequence and an antisense strand sequence of the siRNA, and the siRNA is used for preparing a preparation for promoting Schwann cell survival. According to the invention, the Prl8a9 gene of SCs is knocked down by virtue of a small interfering RNA technology; by improving the proliferation and migration capabilities of the Schwann cells, the apoptosis rate of the Schwann cells is reduced, and the survival rate of the Schwann cells is further improved. Meanwhile, a transcriptome sequencing technology is applied, key genes and pathways of Schwann cells treated by siPr18a9 are deeply excavated, and a theoretical support is provided for research on a repair mechanism after peripheral nerve injury.

Provided herein is a composition comprising GalNAc moiety that can be conjugated to oligonucleotide.The oligonucleotide can be small interfering RNA or antisense oligonucleotide.Also provided herein is a method of treatment comprising administering the composition to a subject.

The invention belongs to the technical field of tumor vaccines, and relates to a cell membrane-derived tumor vaccine with a dendritic cell regulation function and application thereof. The tumor vaccine comprises a tumor cell membrane shell which is subjected to induction treatment to generate immunogenic death, and a cationic carrier core which entraps small interfering RNA (siRNA) and an immunologic adjuvant. According to the preparation method disclosed by the invention, a tumor cell membrane of calreticulin eversion is obtained in a drug induction manner, so that the immunogenicity of the tumor vaccine is improved, and the uptake ability of the dendritic cells to the tumor vaccine is improved; meanwhile, the cation core loaded with siRNA can down-regulate up-regulated negative feedback regulatory factors after the dendritic cells are activated by antigens, inhibit a negative feedback pathway for immunoregulation of the dendritic cells, and enhance the in-vivo immune activation effect of the tumor vaccine.

The invention discloses an application of a secretory curl-associated protein 2 gene as a new target for treating uterine scars, the secretory curl-associated protein 2 gene (sFRP2) promotes the progress of the uterine scars, interferes, silences and inhibits the uterine scars, and the sFRP2 is knocked out, so that the occurrence and development of the scar uterus can be relieved, the pregnancy rate of women can be increased, and the adverse pregnancy outcome can be reduced. In order to further improve the curative effect that sFRP2 gene expression is inhibited by sFRP2-targeted small interfering RNA (issFRP2) so as to inhibit uterine scar formation, ionizable lipid, distearoyl phosphatidylcholine (DSPC), cholesterol and 1, 2-dimyristoyl-rac-glycerol-3-methoxy polyethylene glycol (DMG-PEG) are mixed and dissolved in ethanol according to a certain molar ratio, issFRP2 is dissolved in a citric acid buffer solution, and the issFRP2-targeted small interfering RNA (issFRP2) is added into the citric acid buffer solution so as to obtain a mixed solution; an ethanol phase and a water phase are mixed through a microfluid device, and the mixed solution is dialyzed in a PBS solution for two hours to prepare lipid nanoparticles. And then mixing the polycarbophil, the poloxamer and the lipid nanoparticles to prepare the composite hydrogel. The hydrogel can locally release sisFRP2 in the uterus, inhibit fibrosis, reduce collagen deposition and repair uterine scars. The hydrogel is good in biocompatibility and noninvasive, can realize slow release of the medicine, avoids repeated administration, has no obvious side effect on a maternal body and a fetus, and can also be used for other fibrosis-related diseases.

The invention particularly relates to a glycosylated dendrimer for co-delivery of small interfering RNA (Ribonucleic Acid) and small molecular drugs as well as a preparation method and application of the glycosylated dendrimer. The nano platform provided by the invention is characterized in that an anti-inflammatory drug resveratrol (Res) and electrostatic adsorption small interfering RNA (si-Cp2e1) are loaded in a glycosylated dendrimer G5-Gal. The preparation method and the application comprise the following steps: preparation of G5-Gal, preparation of Res (at) G5-Gal, and preparation of Res (at) G5-Gal / si-Cp2e1. The preparation method is simple, the required raw materials are easy to obtain, the synthesis process is simple and convenient, separation and purification are easy, and the synthesized nano-drug has a liver targeting capability, can realize dual treatment of small molecule drug-small interfering RNA, and has a potential application prospect in the aspect of treatment of alcohol-related liver diseases.

Provided are a small interfering RNA (siRNA) used to inhibit the expression of proprote in convertase subtilisin / kexin type 9 (PCSK9) in a cell, a vector comprising nucleotides encoding same, and a cell, as well as a method using the siRNA, the vector or the cell for the treatment of diseases or symptoms associated with the expression of PCSK9 in a subject.

The invention provides a long-chain non-coding RNA (Ribonucleic Acid) gene and application of small interfering RNA of the long-chain non-coding RNA gene in preparation of a medicine for inhibiting triple negative breast cancer. The nucleotide sequence of the long-chain non-coding RNA gene is as shown in SEQ ID NO. 1. The nucleotide sequence of the small interfering RNA is as shown in SEQ ID NO. 2. The invention also provides application of a reagent for detecting the long-chain non-coding RNA gene in preparation of a kit for diagnosing triple negative breast cancer. The invention also provides application of the long-chain non-coding RNA gene as a therapeutic target in screening of drugs for treating triple negative breast cancer. In-vitro and in-vivo experiments prove that proliferation, migration and invasion of triple negative breast cancer cells are promoted by over-expression of the long-chain non-coding RNA gene; in-vitro and in-vivo experiments prove that the proliferation, migration and invasion of triple negative breast cancer cells can be inhibited by knocking down the long-chain non-coding RNA gene.

Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.

The present disclosure includes, among other things, compositions comprising cyclic peptides with selectivity for adipose tissues. The present disclosure includes, among other things, the recognition that the cyclic peptides with selectivity for adipose tissues can used in targeted delivery of a payload (e.g., an antisense oligonucleotide, or a small interfering RNA) to adipose tissues by conjugating such peptides to the payload. The present disclosure further includes, among other things, compositions comprising cyclic peptide conjugates and their use in the treatment of conditions of adipose tissues.

The invention discloses a bionic bimetallic polyphenol network nano-drug loaded with small non-coding RNA and a preparation method and application thereof, and belongs to the technical field of nano biomedicine.The nano-drug is loaded with small interference through a bimetallic polyphenol network, the surface of the nano-drug is coated with an M1 type macrophage membrane, and the safe and effective nano-drug is formed; the nano-drug acts on macrophages of an inflammation joint part, ROS is synergistically cleared by releasing tannic acid, Cu < 2 + > and small interfering RNA, TNF-alpha expression is inhibited, macrophage polarization is induced, meanwhile, Sr < 2 + > further plays a role in cartilage protection, and the purpose of treating osteoporosis and rheumatoid arthritis is achieved.